asln-6k_20190621.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

June 21, 2019

(Commission File No. 001-38475)

 

ASLAN PHARMACEUTICALS LIMITED

(REG. NO. 289175)

(Translation of registrant’s name into English)

 

CAYMAN ISLANDS

(Jurisdiction of incorporation or organisation)

83 CLEMENCEAU AVENUE

#12-03 UE SQUARE

SINGAPORE 239920

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   Form 40-F  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

    Yes      No  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

    Yes      No  

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

 

 

ASLAN PHARMACEUTICALS LIMITED

(Registrant)

 

 

By:

/s/ Kiran Kumar Asarpota

 

Name:

Kiran Kumar Asarpota

Title:

VP Finance

Date: June 21, 2019

 


 


Announcement of the re-election results of Board of Directors (including independent directors)

 

 

1.

Date of occurrence of the change:  2019/06/21

 

 

2.

Appointment of or changed personnel:  Directors and Independent directors

 

 

3.

Title, name and resume of the replaced person – before:

 

Title:

Name:

Resume:

Chairman

Carl Firth  

Ex-Chairman of the company

Director

Alnair Investment

Representative of director: Jun Wu

Director

BV Healthcare II Pte. Ltd.

Representative of director:Lim Chin Hwee Damien

INED

Andrew James Howden

INED of the company

INED

Chin-Feng Sun      

INED of the company

INED

Robert E. Hoffman

INED of the company

 

 

4.

Title, name and resume of the replacement – after:

 

Title:

Name:

Resume:

Director

Carl Firth  

new-elected director of the company

Director

Alnair Investment

new-elected director of the company; representative of director – Jun Wu

Director

BV Healthcare II Pte. Ltd.

new-elected director of the company; representative of director – Lim Chin Hwee Damien

INED

Andrew James Howden

new-elected INED of the company

INED

Chin-Feng Sun      

new-elected INED of the company

INED

Robert E. Hoffman

new-elected INED of the company

 

 

 

5.

Type of change: expiry of term of office

 

 

6.

Reason for the change: Re-election

 

 

7.

Number of shares held by the new personnel at the time of appointment:

 

Title:

Name:

Number of shares

Director

Carl Firth  

0 shares *

Director

Alnair Investment

8,823,528 shares **

Director

BV Healthcare II Pte. Ltd.

7,542,112 shares

INED

Andrew James Howden

439,510 shares

INED

Chin-Feng Sun      

0 shares

INED

Robert E. Hoffman

0 shares

 

 

 

8.

Original term:   from 2016/04/15 to 2019/04/14

 

 


 

9.

Effective date of the new appointment:  2019/06/21

 

 

10.

Rate of turnover of directors of the same term: NA

 

 

11.

Rate of turnover of supervisors of the same term: NA

 

 

12.

Rate of turnover of independent directors of the same term: NA

 

 

13.

Change in one-third or more of directors (“Yes” or “No”): Yes

 

 

14.

Any other matters that need to be specified:

 

* Director Carl Firth holds his shares under a company Kimba Capital and the total number of shares are 3,344,340.

 

** Director Alnair Investment holds shares under a company Shanghai Cenova and the total number of shares are 1,063,830.